Endometrial Cancer Patients Not Offered Genetic Counseling Referrals

Article

According to a study recently presented at the 2017 American Society of Clinical Oncology Annual Meeting, held June 2–6 in Chicago, women diagnosed with endometrial cancer are oftentimes not provided with genetic counseling referrals.

According to a study recently presented (abstract 1503) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago, women diagnosed with endometrial cancer are oftentimes not provided with genetic counseling referrals (GCR).

Many clinicians are familiar with Lynch syndrome, the hereditary genetic mutation syndrome also referred to as hereditary nonpolyposis colorectal cancer (HNPCC). Currently it is understood that the specific DNA mismatch repair (MMR) genes (genes responsible for repairing DNA errors during cell division) which affect those with HNPCC include the genes MLH1, MSH2, MSH6, PMS2, and EPCAM, leading to an increased risk in certain cancers at an earlier than average onset. Some of these cancers include stomach, small intestine, liver, gallbladder ducts, upper urinary tract, brain, and skin. Additionally, women with this disorder are also at an increased risk of ovarian and endometrial cancers.

Researchers addressed the relevance of genetic testing in certain populations of women diagnosed with endometrial cancer. Their aim was to gain a better understanding of genetic counseling referrals and genetic testing rates in this population.

Between 2012 and 2015, they identified women diagnosed with endometrial cancer (n = 447) and evaluated their risk factors. These included age, body mass index (BMI), family history of two or more Lynch-related cancer family members, and tumor MMR protein expression loss. Of the 447 women identified, gynecologic oncologists referred 107 women (24%) of these women based on their own discretion and included women who were younger and with a lower BMI. Of these referrals, 71 women (66%) went on to receive testing and eight women (11%) were found to have a germline mutation in one of the MMR genes.

Researchers are recommending that high-risk women with endometrial cancer receive genetic counseling referrals and testing to identify women at a higher than average risk for a germline mutation. The goal of capturing these Lynch-positive women is to adequately screen for other cancers in which they are also at risk for developing. Additionally, appropriate family member testing may also be recommended.

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Related Content